Literature DB >> 30096312

Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis.

Kosaku Nanki1, Kohta Toshimitsu1, Ai Takano1, Masayuki Fujii1, Mariko Shimokawa1, Yuki Ohta1, Mami Matano1, Takashi Seino1, Shingo Nishikori2, Keiko Ishikawa1, Kenta Kawasaki1, Kazuhiro Togasaki1, Sirirat Takahashi1, Yasutaka Sukawa1, Hiroki Ishida3, Shinya Sugimoto1, Hirofumi Kawakubo3, Jihoon Kim4, Yuko Kitagawa3, Shigeki Sekine5, Bon-Kyoung Koo4, Takanori Kanai1, Toshiro Sato6.   

Abstract

Recent sequencing analyses have shed light on heterogeneous patterns of genomic aberrations in human gastric cancers (GCs). To explore how individual genetic events translate into cancer phenotypes, we established a biological library consisting of genetically engineered gastric organoids carrying various GC mutations and 37 patient-derived organoid lines, including rare genomically stable GCs. Phenotype analyses of GC organoids revealed divergent genetic and epigenetic routes to gain Wnt and R-spondin niche independency. An unbiased phenotype-based genetic screening identified a significant association between CDH1/TP53 compound mutations and the R-spondin independency that was functionally validated by CRISPR-based knockout. Xenografting of GC organoids further established the feasibility of Wnt-targeting therapy for Wnt-dependent GCs. Our results collectively demonstrate that multifaceted genetic abnormalities render human GCs independent of the stem cell niche and highlight the validity of the genotype-phenotype screening strategy in gaining deeper understanding of human cancers.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR-Cas9; Gastric cancers; Organoids; Stem cell niche; Wnt signaling

Mesh:

Substances:

Year:  2018        PMID: 30096312     DOI: 10.1016/j.cell.2018.07.027

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  83 in total

1.  Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer.

Authors:  Manjie Xing; Wen Fong Ooi; Jing Tan; Aditi Qamra; Po-Hsien Lee; Zhimei Li; Chang Xu; Nisha Padmanabhan; Jing Quan Lim; Yu Amanda Guo; Xiaosai Yao; Mandoli Amit; Ley Moy Ng; Taotao Sheng; Jing Wang; Kie Kyon Huang; Chukwuemeka George Anene-Nzelu; Shamaine Wei Ting Ho; Mohana Ray; Lijia Ma; Gregorio Fazzi; Kevin Junliang Lim; Giovani Claresta Wijaya; Shenli Zhang; Tannistha Nandi; Tingdong Yan; Mei Mei Chang; Kakoli Das; Zul Fazreen Adam Isa; Jeanie Wu; Polly Suk Yean Poon; Yue Ning Lam; Joyce Suling Lin; Su Ting Tay; Ming Hui Lee; Angie Lay Keng Tan; Xuewen Ong; Kevin White; Steven George Rozen; Michael Beer; Roger Sik Yin Foo; Heike Irmgard Grabsch; Anders Jacobsen Skanderup; Shang Li; Bin Tean Teh; Patrick Tan
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 2.  Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids.

Authors:  Ryan C Smith; Viviane Tabar
Journal:  Cell Stem Cell       Date:  2018-12-20       Impact factor: 24.633

3.  Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.

Authors:  Jie Li; Huawei Xu; Lixing Zhang; Lele Song; Dan Feng; Xiaobo Peng; Meihong Wu; Yang Zou; Bin Wang; Lixing Zhan; Guoqiang Hua; Xianbao Zhan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-09       Impact factor: 4.553

4.  Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology.

Authors:  Zahra Dantes; Hsi-Yu Yen; Nicole Pfarr; Christof Winter; Katja Steiger; Alexander Muckenhuber; Alexander Hennig; Sebastian Lange; Thomas Engleitner; Rupert Öllinger; Roman Maresch; Felix Orben; Irina Heid; Georgios Kaissis; Kuangyu Shi; Geoffrey Topping; Fabian Stögbauer; Matthias Wirth; Katja Peschke; Aristeidis Papargyriou; Massoud Rezaee-Oghazi; Karin Feldmann; Arlett Pg Schäfer; Raphela Ranjan; Clara Lubeseder-Martellato; Daniel E Stange; Thilo Welsch; Marc Martignoni; Güralp O Ceyhan; Helmut Friess; Alexander Herner; Lucia Liotta; Matthias Treiber; Guido von Figura; Mohamed Abdelhafez; Peter Klare; Christoph Schlag; Hana Algül; Jens Siveke; Rickmer Braren; Gregor Weirich; Wilko Weichert; Dieter Saur; Roland Rad; Roland M Schmid; Günter Schneider; Maximilian Reichert
Journal:  JCI Insight       Date:  2020-08-06

5.  Organoid biobanks as a new tool for pre-clinical validation of candidate drug efficacy and safety.

Authors:  Gerardo Botti; Maurizio Di Bonito; Monica Cantile
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-02-15

Review 6.  Phenotypic screening system using three-dimensional (3D) culture models for natural product screening.

Authors:  Hikaru Suenaga; Noritaka Kagaya; Manabu Kawada; Daisuke Tatsuda; Toshiro Sato; Kazuo Shin-Ya
Journal:  J Antibiot (Tokyo)       Date:  2021-07-29       Impact factor: 2.649

Review 7.  Modeling colorectal cancers using multidimensional organoids.

Authors:  Ibrahim M Sayed; Amer Ali Abd El-Hafeez; Priti P Maity; Soumita Das; Pradipta Ghosh
Journal:  Adv Cancer Res       Date:  2021-03-26       Impact factor: 6.242

Review 8.  Organoid models of gastrointestinal cancers in basic and translational research.

Authors:  Harry Cheuk Hay Lau; Onno Kranenburg; Haipeng Xiao; Jun Yu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-25       Impact factor: 46.802

Review 9.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

10.  Applications of Organoids for Cancer Biology and Precision Medicine.

Authors:  Yuan-Hung Lo; Kasper Karlsson; Calvin J Kuo
Journal:  Nat Cancer       Date:  2020-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.